CDK7 Inhibition Is Effective in all the Subtypes of Breast Cancer: Determinants of Response and Synergy with EGFR Inhibition

CDK7, a transcriptional cyclin-dependent kinase, is emerging as a novel cancer target. Triple-negative breast cancers (TNBC) but not estrogen receptor-positive (ER+) breast cancers have been reported to be uniquely sensitive to the CDK7 inhibitor THZ1 due to the inhibition of a cluster of TNBC-speci...

Descripción completa

Detalles Bibliográficos
Autores principales: McDermott, Martina S. J., Sharko, Amanda C., Munie, Jessica, Kassler, Susannah, Melendez, Theresa, Lim, Chang-uk, Broude, Eugenia V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140476/
https://www.ncbi.nlm.nih.gov/pubmed/32155786
http://dx.doi.org/10.3390/cells9030638

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140476/
https://www.ncbi.nlm.nih.gov/pubmed/32155786
http://dx.doi.org/10.3390/cells9030638

Ejemplares similares